AgoneX Biopharmaceuticals Inc.
🇺🇸United States
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis
Phase 2
- Conditions
- Migraine Prophylaxis
- Interventions
- Drug: Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- AgoneX Biopharmaceuticals, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT02021474
© Copyright 2025. All Rights Reserved by MedPath